Is pleased to announce the completion of the search for the President & Chief Executive Officer for
Akorn Pharmaceuticals, a publicly-traded corporation.
As announced by the company earlier, “Douglas S. Boothe has been named president and chief executive officer effective January 1, 2019, bringing deep pharmaceuticals expertise and a proven track record as Akorn looks forward to its next phase as an independent company committed to rebuilding shareholder value.
Boothe is an industry veteran with extensive accomplishments in the specialty, generic and over-the-counter pharmaceuticals business. He brings to Akorn a long history of senior level expertise in general management, strategy, sales and marketing, product selection, supply chain and business development in the US and global arenas.”
This search has been successfully completed.